New drug aims to reduce bulging eyes in thyroid disease

NCT ID NCT07113262

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests IBI311 (teprotumumab) in 111 people with inactive thyroid eye disease. The main goal is to see if the drug can reduce eye bulging by at least 2 mm after 24 weeks. Participants receive either the drug or a placebo, and the study lasts up to 64 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI311 (teprotumumab injection)
What this could lead to: If it works, this could provide a treatment option to reduce eye bulging in people with inactive thyroid eye disease.
What could go wrong: This is a Phase 3 trial, but results may not confirm benefit. Side effects are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

The First Affiliated Hospital of Medical University
RECRUITING

Shenyang, Liaoning, 110801, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.